IP Library › Granted Patent US 10,105,394
Granted Patent B2
US 10,105,394 · App. 15/055,221 · Granted Oct 23, 2018

Method of treating graft versus host disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,105,394
App. No.
15/055,221
Granted
Oct 23, 2018
Kind
B2
Abstract

A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1 bright cells and/or progeny thereof and/or soluble factors derived therefrom.

Claims (13)

1. A method for preventing the development of or treating graft versus host disease (GvHD) complications in a human patient undergoing or about to undergo a bone marrow or hematopoietic stem cell transplantation, which method comprises administering, to the human patient, an effective amount of a population of cells enriched for STRO-1 bright multipotential cells, or multipotential cells culture-expanded from STRO-1 bright cells, wherein the cells in the administered population are CD34 − .

2. The method according to claim 1 , wherein the administered population is administered to the human patient prior to undergoing the transplantation.

3. The method according to claim 1 , wherein the bone marrow or hematopoietic stem cell transplantation is an allogeneic transplantation.

4. The method according to claim 1 , wherein the administered population is allogeneic.

5. The method according to claim 1 , wherein the population is administered systemically.

6. The method according to claim 5 , wherein the population is administered by intravenous injection.

7. The method of claim 1 , wherein the administered population comprises between 0.1×10 6 to 5×10 6 cells.

8. The method of claim 1 , wherein the administered population comprises between 0.3×10 6 to 2×10 6 cells.

9. The method of claim 1 , wherein the administered population comprises between 0.1×10 5 and 0.5×10 6 cells.

10. The method of claim 9 , wherein the administered population comprises about 0.3×10 6 cells.

11. The method of claim 1 , wherein the administered population is administered once weekly or less often.

12. The method according to claim 1 , wherein the human patient is suffering from aplastic anemia, myelofibrosis, or bone marrow failure following chemotherapy and radiation therapy.

13. The method according to claim 1 , further comprising administering an immunosuppressive drug to the human patient.

Assignments (5)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0682 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST, INC.
Reel/Frame 072294/0555 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2018
From: ITESCU, SILVIU; SCHUSTER, MICHAEL DAVID
To: MESOBLAST, INC.
Reel/Frame 045894/0517 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST, INC.
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0682 →